Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME‐CHF trial-Reference-Cited by-同舟云学术

Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME‐CHF trial

Published:2020-02-05 Issue:4 Volume:22 Page:701-709
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Stöhr Robert¹,Brandenburg Vincent M.²,Heine Gunnar H.³,Maeder Micha T.⁴,Leibundgut Gregor⁵,Schuh Alexander¹,Jeker Urs⁶,Pfisterer Matthias⁷,Sanders‐van Wijk Sandra⁸,Brunner‐la Rocca Hans‐Peter⁷⁸

Affiliation:

1. Department of Internal Medicine I University Hospital Aachen RWTH Aachen University Germany

2. Department of Cardiology and Nephrology Rhein‐Maas Klinikum Würselen Germany

3. AGAPLESION MARKUS KRANKENHAUS Frankfurt am Main Germany

4. Department of Cardiology Kantonsspital St. Gallen St. Gallen Switzerland

5. Department of Internal Medicine, Cardiology Kantonsspital Baselland Liestal Switzerland

6. Heart Center, Luzerner Kantonsspital Lucerne Switzerland

7. Department of Cardiology University Hospital Basel Basel Switzerland

8. Department of Cardiology Maastricht University Medical Center Maastricht The Netherlands

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.1749

Reference43 articles.

1. FGF-23 and secondary hyperparathyroidism in chronic kidney disease

2. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders

3. The role of vitamin D in cardiovascular disease: From present evidence to future perspectives

4. Update on fibroblast growth factor 23 in chronic kidney disease

5. Fibroblast Growth Factor-23 and Cardiovascular Events in CKD

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomic Associations of Adverse Outcomes in Human Heart Failure;Journal of the American Heart Association;2024-03-05

2. HFpEF: New biomarkers and their diagnostic and prognostic value;Current Problems in Cardiology;2024-01

3. Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction;BMC Cardiovascular Disorders;2023-09-01

4. Evidence-based perspective on heart failure and osteoporosis: a systematic review;Russian Journal of Cardiology;2023-04-15

5. Heart failure: an update from the last years and a look at the near future;ESC Heart Failure;2022-12